Welcome to our dedicated page for Aridis Pharmaceuticals SEC filings (Ticker: ARDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aridis Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aridis Pharmaceuticals's regulatory disclosures and financial reporting.
Aridis Pharmaceuticals reports a Schedule 13G/A showing Armistice Capital, LLC and Steven Boyd beneficially own 5,096,251 shares, representing 11.43% of the common stock (CUSIP 040334104). The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and Mr. Boyd, as managing member, may be deemed to beneficially own the shares. The Master Fund is identified as the direct holder and is described as having the right to receive dividends or sale proceeds.